✦ LIBER ✦

A Prospective Phase I/II Trial of Bortezomib-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation: Encouraging Safety, Efficacy, and Survival

✍ Scribed by J. Koreth; K.E. Stevenson; H.T. Kim; B. Bindra; S. McDonough; V.T. Ho; C.S. Cutler; P. Armand; R.J. Soiffer; J.H. Antin; J. Ritz; E.P. Alyea

Book ID: 116282012
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 83 KB
Volume: 17
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2010.12.044

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib, tacrolimus, and methotrexate

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

✍ Koreth, J.; Stevenson, K. E.; Kim, H. T.; Garcia, M.; Ho, V. T.; Armand, P.; Cut 📂 Article 📅 2009 🏛 American Society of Hematology 🌐 English ⚖ 206 KB

Phase II Prospective Multicenter Study o

Phase II Prospective Multicenter Study of Treosulfan Based Reduced intensity Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor

✍ M. Michallet; M. Sobh; S. Morisset; N. Tedone; J.O. Bay; J.-L. Harousseau; M. Mo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Feasibility, Safety and Efficacy of Mara

Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study

✍ R. Reshef; S.M. Luger; A.W. Loren; N.V. Frey; S.C. Goldstein; E.O. Hexner; E.A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB